title: Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
abstract: We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine, with one of three dosage regimens: for 5 days (AZA 5); 7 days including a 2-day break (AZA 5-2-2); or 7 days (AZA 7); all 28-day cycles. Overall response rates were 39.4%, 67.9%, and 51.3%, respectively, and median overall survival (OS) durations were 13.2, 19.1, and 14.9 months. Neutropenia was the most common grade 3-4 adverse event. These results suggest better effectiveness-tolerability profiles for 7-day schedules.
authors.affiliation: Hospital Universitario Virgen de la Victoria, Málaga, Spain. Electronic address: reginagarciadel@yahoo.es.
authors.forename: Regina
authors.initials: R
authors.lastname: García-Delgado
authors.affiliation: Hospital Universitario de Guadalajara, Madrid, Spain.
authors.forename: Dunia
authors.initials: D
authors.lastname: de Miguel
authors.affiliation: Hospital Carlos Haya, Málaga, Spain.
authors.forename: Alicia
authors.initials: A
authors.lastname: Bailén
authors.affiliation: Hospital Clínico Universitario, Salamanca, Spain.
authors.forename: José Ramón
authors.initials: JR
authors.lastname: González
authors.affiliation: Hospital Son Llatzer, Palma de Mallorca, Spain.
authors.forename: Joan
authors.initials: J
authors.lastname: Bargay
authors.affiliation: Hospital Universitario Virgen del Rocío, IBIS, Seville, Spain.
authors.forename: José F
authors.initials: JF
authors.lastname: Falantes
authors.affiliation: Hospital Doctor Peset, Valencia, Spain.
authors.forename: Rafael
authors.initials: R
authors.lastname: Andreu
authors.affiliation: Hospital General de León, León, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Ramos
authors.affiliation: Hospital Clínico Universitario de Valencia, Valencia, Spain.
authors.forename: Mar
authors.initials: M
authors.lastname: Tormo
authors.affiliation: Hospital Santa Creu i Sant Pau, Barcelona, Spain.
authors.forename: Salut
authors.initials: S
authors.lastname: Brunet
authors.affiliation: Hospital Virgen Macarena, Seville, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Figueredo
authors.affiliation: Hospital Reina Sofia, Córdoba, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Casaño
authors.affiliation: Hospital Costa del Sol, Marbella, Spain.
authors.forename: Angeles
authors.initials: A
authors.lastname: Medina
authors.affiliation: Servei d'Estadística Aplicada, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Llorenç
authors.initials: L
authors.lastname: Badiella
authors.affiliation: Hospital Juan Ramón Jiménez, Huelva, Spain, on behalf of the Asociación Andaluza de Hematología y Hemoterapia, Spain.
authors.forename: Antonio Fernández
authors.initials: AF
authors.lastname: Jurado
authors.affiliation: Hospital Universitario La Fe, Valencia, Spain.
authors.forename: Guillermo
authors.initials: G
authors.lastname: Sanz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D001374:Azacitidine / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D012189:Retrospective Studies
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine
keywords: Acute myeloid leukemia; Azacitidine; Dosing schedules; Myelodysplastic syndromes; Overall survival; Safety